RU95108385A - Пептиды, способ их получения, фармацевтическая композиция и способ ее получения - Google Patents

Пептиды, способ их получения, фармацевтическая композиция и способ ее получения

Info

Publication number
RU95108385A
RU95108385A RU95108385/04A RU95108385A RU95108385A RU 95108385 A RU95108385 A RU 95108385A RU 95108385/04 A RU95108385/04 A RU 95108385/04A RU 95108385 A RU95108385 A RU 95108385A RU 95108385 A RU95108385 A RU 95108385A
Authority
RU
Russia
Prior art keywords
peptides
synthesis
preparing
pharmaceutical composition
biology
Prior art date
Application number
RU95108385/04A
Other languages
English (en)
Other versions
RU2146262C1 (ru
Inventor
Комолио Паоло
It]
Понцетто Карола
Original Assignee
Фармациа С.п.А. (IT)
Фармациа С.п.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939313528A external-priority patent/GB9313528D0/en
Priority claimed from GB9407673A external-priority patent/GB9407673D0/en
Application filed by Фармациа С.п.А. (IT), Фармациа С.п.А. filed Critical Фармациа С.п.А. (IT)
Publication of RU95108385A publication Critical patent/RU95108385A/ru
Application granted granted Critical
Publication of RU2146262C1 publication Critical patent/RU2146262C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение относится к биологии клеток, в частности, к новым пептидам, обладающим способностью взаимодействовать с внутриклеточным трансдуктором сигнала, препятствуя тем самым процессу передачи сигнала, приводящему к пролиферации и подвижности клеток. Пептиды могут быть синтезированы из отдельных аминокислот и/или из предварительно полученных пептидов, состоящих из двух или более аминокислотных остатков. Пептиды могут быть с успехом использованы для лечения опухолевых заболеваний.

Claims (1)

  1. Изобретение относится к биологии клеток, в частности, к новым пептидам, обладающим способностью взаимодействовать с внутриклеточным трансдуктором сигнала, препятствуя тем самым процессу передачи сигнала, приводящему к пролиферации и подвижности клеток. Пептиды могут быть синтезированы из отдельных аминокислот и/или из предварительно полученных пептидов, состоящих из двух или более аминокислотных остатков. Пептиды могут быть с успехом использованы для лечения опухолевых заболеваний.
RU95108385A 1993-06-30 1994-06-15 Пептиды, способ их получения, фармацевтическая композиция и способ ее получения RU2146262C1 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US9313528.3 1993-06-30
GB939313528A GB9313528D0 (en) 1993-06-30 1993-06-30 Peptide inhibitors of mitogenesis and motogenesis
US9407673.4 1994-04-18
GB9407673A GB9407673D0 (en) 1994-04-18 1994-04-18 Peptide inhibitors of mitogenesis and motogenius
US9407673,4 1994-04-18
PCT/EP1994/001943 WO1995001376A1 (en) 1993-06-30 1994-06-15 Peptide inhibitors of mitogenesis and motogenesis

Publications (2)

Publication Number Publication Date
RU95108385A true RU95108385A (ru) 1997-03-20
RU2146262C1 RU2146262C1 (ru) 2000-03-10

Family

ID=26303150

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95108385A RU2146262C1 (ru) 1993-06-30 1994-06-15 Пептиды, способ их получения, фармацевтическая композиция и способ ее получения

Country Status (15)

Country Link
US (2) US5594105A (ru)
EP (1) EP0662090A1 (ru)
JP (1) JP3585044B2 (ru)
KR (1) KR950703003A (ru)
CN (1) CN1056153C (ru)
AU (1) AU670704B2 (ru)
CA (1) CA2142713A1 (ru)
FI (1) FI950729A (ru)
HU (1) HU219813B (ru)
IL (1) IL110160A (ru)
MY (1) MY130026A (ru)
NZ (1) NZ268006A (ru)
PL (1) PL179628B1 (ru)
RU (1) RU2146262C1 (ru)
WO (1) WO1995001376A1 (ru)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09512704A (ja) * 1994-03-17 1997-12-22 ナシヨナル・ジユーイツシユ・センター・フオー・イミユノロジー・アンド・レスピラトリー・メデイシン シグナル変換経路を調節するための産物および方法
US5744313A (en) * 1994-12-09 1998-04-28 The Regents Of The University Of California Assay employing novel protein domain which binds tyrosine phosphorylated proteins
US5807989A (en) * 1994-12-23 1998-09-15 New York University Methods for treatment or diagnosis of diseases or disorders associated with an APB domain
US6107457A (en) * 1995-02-16 2000-08-22 Board Of Regents, The University Of Texas System Bcr-Abl directed compositions and uses for inhibiting Philadelphia chromosome stimulated cell growth
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
GB9603227D0 (en) * 1996-02-15 1996-04-17 Pharmacia Spa Peptide antagonists of cellular mitogenesis and motogenesis and their therapeutic use
EP1115847A1 (en) 1998-09-25 2001-07-18 Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
EP1163262B1 (en) * 1999-03-23 2011-05-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Phenylalanine derivatives
US7226991B1 (en) * 1999-03-23 2007-06-05 United States Of America, Represented By The Secretary, Department Of Health And Human Services Phenylalanine derivatives
IL131142A0 (en) * 1999-07-28 2001-01-28 Rad Ramot Prognosis of breast cancer and other diseases
JP2003512334A (ja) 1999-10-22 2003-04-02 アメリカ合衆国 Ｇｒｂ−２ｓｈ−２ドメインの阻害剤による細胞運動性及び脈管形成の阻害
US7871981B2 (en) * 1999-10-22 2011-01-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell motility, angiogenesis, and metastasis
WO2001049709A1 (en) 2000-01-03 2001-07-12 Ramot University Authority For Applied Research & Industrial Development Ltd. Glycogen synthase kinase-3 inhibitors
US6977241B2 (en) * 2000-08-22 2005-12-20 The United States Of America As Represented By The Department Of Health & Human Services SH2 domain binding inhibitors
US7425537B2 (en) * 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
US7378432B2 (en) 2001-09-14 2008-05-27 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
EP1654377A4 (en) * 2002-03-01 2010-03-24 Roger Williams Hospital PROCESSES AND COMPOSITIONS RELATED TO THE SHC PROTEIN FOR THE PROGNOSIS OF BREAST, PROSTATE AND EGG CANCER
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
AU2003286411A1 (en) 2002-12-12 2004-06-30 Tel Aviv University Future Technology Development L.P. Glycogen synthase kinase-3 inhibitors
US20040138104A1 (en) * 2003-01-14 2004-07-15 The Government Of The United States Of America Represented By The Secretary, Peptides
US7189694B2 (en) * 2003-04-18 2007-03-13 University Of Florida Research Foundation, Inc. Inhibitors of autophosphorylation protein kinases
US20050119163A1 (en) * 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
DK1773885T3 (da) 2004-08-05 2010-08-16 Genentech Inc Humaniserede anti-c-met-antagonister
WO2006113767A2 (en) 2005-04-15 2006-10-26 Genentech, Inc. Hgf beta chain variants
AU2006315651A1 (en) * 2005-11-11 2007-05-24 Roger Williams Hospital P66-Shc as predictive marker in cancer treatment
US20090054366A1 (en) * 2007-06-15 2009-02-26 Reliance Life Sciences Pvt. Ltd. RNAi MEDIATED KNOCKDOWN OF NUMA FOR CANCER THERAPY
JP5337043B2 (ja) * 2007-10-15 2013-11-06 中外製薬株式会社 異種タンパク質を高生産する細胞の作製方法
IT1397874B1 (it) * 2008-09-30 2013-02-04 Multimedica Holding S P A Uso di peptidi nella terapia antiangiogenica
IT1397873B1 (it) * 2008-09-30 2013-02-04 Multimedica Holding S P A Uso di peptidi nella terapia antiangiogenica relativa a patologie tumorali
US20130004484A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
RU2016141385A (ru) 2014-03-24 2018-04-28 Дженентек, Инк. Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf
CN105504017B (zh) * 2014-05-29 2019-05-03 天津久益生物科技有限公司 一种治疗癌症的肽变体及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362716A (en) * 1989-12-27 1994-11-08 The United States Of America As Represented By The Department Of Health And Human Services Methods for stimulating hematopoietic progenitors using hepatocyte growth factor and lymphokines
EP0584125B1 (en) * 1991-05-10 1997-07-16 PHARMACIA & UPJOHN S.p.A. Truncated forms of the hepatocyte growth factor (hgf) receptor
DE4136443A1 (de) * 1991-11-06 1993-05-13 Boehringer Ingelheim Int Expression der reifen proteinase 2a, ihre partielle reinigung und bereitstellung kompetitiv wirkender substrate
US7642971B2 (en) * 2007-05-25 2010-01-05 Sony Ericsson Mobile Communications Ab Compact diversity antenna arrangement

Also Published As

Publication number Publication date
PL307742A1 (en) 1995-06-12
US5594105A (en) 1997-01-14
JP3585044B2 (ja) 2004-11-04
AU670704B2 (en) 1996-07-25
IL110160A0 (en) 1994-10-07
NZ268006A (en) 1996-09-25
IL110160A (en) 2000-06-29
FI950729A (fi) 1995-04-19
MY130026A (en) 2007-05-31
CN1111455A (zh) 1995-11-08
CN1056153C (zh) 2000-09-06
PL179628B1 (pl) 2000-10-31
WO1995001376A1 (en) 1995-01-12
RU2146262C1 (ru) 2000-03-10
FI950729A0 (fi) 1995-02-17
HU9500919D0 (en) 1995-05-29
US5912183A (en) 1999-06-15
KR950703003A (ko) 1995-08-23
AU7071894A (en) 1995-01-24
JPH08500845A (ja) 1996-01-30
CA2142713A1 (en) 1995-01-12
HU219813B (hu) 2001-08-28
HUT71324A (en) 1995-11-28
EP0662090A1 (en) 1995-07-12

Similar Documents

Publication Publication Date Title
RU95108385A (ru) Пептиды, способ их получения, фармацевтическая композиция и способ ее получения
Rucavado et al. Local tissue damage induced by BaP1, a metalloproteinase isolated from Bothrops asper (Terciopelo) snake venom
RU94016384A (ru) Лизосомные расщепляемые ферментами противоопухолевые лекарственные коньюгаты
RU95110938A (ru) Производные 1-(2-оксоацетил)пиперидин-2-карбоновых кислот, фармацевтическая композиция, способ лечения, способ получения
RU94040170A (ru) Изохинолины
Wang et al. Twelve antioxidant peptides from protein hydrolysate of Skipjack tuna (Katsuwonus pelamis) roe prepared by flavourzyme: Purification, sequence identification, and activity evaluation
AR006188A1 (es) "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
AU3368497A (en) Human dnase i hyperactive variants
HUP0400231A2 (hu) Rákos megbetegedések kezelésében különösen hasznos, immundecepcióra szolgáló eljárások és gyógyszerkészítmények
RU94044534A (ru) Амино-производные тиазола, способы их получения и содержащие их фармацевтические композиции
DK1259536T3 (da) Fremgangsmåder til peptidfremstilling
NO308396B1 (no) FremgangsmÕte ved fremstilling av substanser av polypeptidnatur
EP0421023B1 (de) Katabolische Enzyme zur Induktion des Tumornekrose-Faktors (TNF)
ATE40556T1 (de) Verfahren zur synthese von peptiden.
ATE98869T1 (de) Pharmazeutisches mittel fuer behandlung von menschlichem krebs und verfahren zu seiner herstellung.
CN105131089B (zh) 一种十三肽及其应用
EP1858913B1 (de) Peptid-mimetika und ihre verwendung als inhibitoren des 20s proteasoms, 26s proteasoms und des immunoproteasoms
Langlais et al. The phospholipase A2 of human spermatozoa; purification and partial sequence
CS55990A3 (en) Phenylhydrazones, process of their preparation and cosmetic preparations and pharmaceuticals made therefrom
FI964186A (fi) Ei-liittävät gp350/220-variantit
RU94028283A (ru) Фармацевтический препарат, способ его получения, способ лечения, используя указанный препарат
Hakobyan et al. Synthesis of (S)-alanyl-(S)-β-(thiazol-2-yl-carbamoyl)-α-alanine, dipeptide containing it and in vitro investigation of the antifungal activity
AU2001220255A1 (en) Human cervical cancer suppressor protein, polynucleotide encoding the protein, cell transformed with the polynucleotide and method for suppressing proliferationof cancer cell using the expression vector
RU94004998A (ru) Хризоспермины, способ их получения, лекарственное средство на их основе и штамм apiocrea chrysosperma
Okada et al. A new pyroglutamylpeptide (Pyr-Lys-Ser) isolated from the venom of Agkistrodon halys blomhoffii